Impaired glucose tolerance and impaired fasting glucose - A review of diagnosis, clinical implications and management

Diabetes and Vascular Disease Research

Volumn 2, Issue 1, 2005, Pages 9-15

  Petersen, John L ^a,b   McGuire, Darren K ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Impaired fasting glucose; Impaired glucose tolerance; Prevention; Screening; Therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; PLACEBO; RAMIPRIL; RENIN; ROSIGLITAZONE; ROSUVASTATIN; TROGLITAZONE; UNINDEXED DRUG; VALSARTAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES CONTROL; DIAGNOSTIC ACCURACY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; ENDOTHELIUM LESION; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OUTCOMES RESEARCH; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; WEIGHT REDUCTION;

EID: 14744285326     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2005.007     Document Type: Review

References (71)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000;23:S4-S19.
3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications part 1: diagnosis and classification of diabetes mellitus. Diabetic Med 1998;15:539-53.
4. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program. NIH Publication No. 01-3670, May 2001; Bethesda, MD.
5. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999.
6. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. Diabetes Care 1999;22: 233-40.
8. Khaw KT, Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001;322:1-6.
9. Edelstein SL, Knowler WC, Bain RP et al. Predictors of progression from impaired fasting glucose to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701-10.
10. Shimokata H, Muller DC, Fleg JL, Sorkin J, Ziemba AW, Andres R. Age as independent determinant of glucose tolerance. Diabetes 1991;40: 44-51.
11. de Vegt F, Dekker JM, Jager A et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA 2001;285:2109-13.
12. Fuller JH, Shipley MJ, Rose, G, Jarrett JR, Keen H. Coronary heart disease and impaired glucose tolerance. Lancet 1980;l:1373-6.
13. Knowler WC, Pettitt DJ. Six year incidence of microvascular complications confirms the need to reassess diagnostic criteria for diabetes. Excerpta Medica International Congress Serial 1979;122:481.
14. Balkau B, Eschwege E, Papoz L et al. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ 1993;307:295-9.
15. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: The Chicago Heart Association detection project in industry study. Diabetes Care 1997;20:163-9.
16. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
17. McCance DR, Hanos RL, Charlse MA et al. Comparison of tests for glycated hemoglobin and fasting and two hour plasma glucose concentration as diagnostic methods for diabetes. BMJ 1994;308:1323-8.
18. Engelgau MM, Thompson TJ, Herman WH et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care 1997;20:785-91.
19. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrot M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clinical Chemistry 2002; 48:436-72.
20. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999;22:696-9.
21. Gabir MM, Hanson RL, Dabelea D et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000;23:1108-12.
22. Shaw JE, Zimmett PZ, Hodge AM et al. Impaired fasting glucose: how low should it go? Diabetes Care 2000;23:34-9.
23. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose and diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Care 1997;20:935-42.
24. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999;354:617-21.
25. Fisman EZ, Motro M, Tenenbaum A, Boyko V, Andelzweig L, Behar S. Impaired fasting glucose concentrations in non-diabetic patients with ischemic heart disease: a marker for worse prognosis. Am Heart J 2001; 141:485-90.
26. Muhlestein JB, Anderson JL, Horne BD et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003;146:351-8.
27. Shaw JE, de Courten MR Hodge AM et al. IGT or IFC for predicting NIDDM: who is right, WHO or ADA? Diabetologia 1998;41:A3.
28. The DECODE Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype with diabetes? Reanalysis of European epidemiological data. BMJ 1998;317:371-5.
29. Mannucci E, De Bellis A, Cernigoi AM, Tortul C, Totella C, Velussi M. Further data on the comparison between World Health Organization and American Diabetes Association diagnostic criteria. Diabetes Care 1999;22:1755-6.
30. Barzialy JI, Spiekerman CF, Wahl PW et al. Cardiovascular disease in older adults with glucose disorders: comparison of the American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 1999;354:622-5.
31. Gomez-Perez FJ, Aguilar-Salinas Ca, Lopez-Alvarenga JC, Perez-Jauregui J, Guillen-Pineda LE, Rull JA. Lack of agreement between the World Health Organization category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose. Diabetes Care 1998;21:1886-8.
32. Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care 1999;22:1490-3.
33. The DECODE Investigators. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96.
34. Smith NL, Barzilay JI, Shaffer D et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly. Arch Intern Med 2002;162:209-16.
35. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Similar 9-year mortality risk and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories. Diabetes Care 2000;23:40-4.
36. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:777-83.
37. Lilloja S, Mott DM, Spraul M et al. Insulin resistance and insulin secretatory dysfunction as precursors of non-insulin dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993;329: 1988-92.
38. Haffner SM, Miettinen H, Gaskill SP et al. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of non-insulin dependent diabetes mellitus. Diabetes 1995;44: 1386-91.
39. Festa A, Hanley AJ, Tracy RP, D'Agostino R, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003;108:1822-30.
40. Feskens EJ, Tuomilehto J, Stengard JH, Pekkanen J, Nissinen A, Kromhout D. Hypertension and overweight associated with hyperinsulinemia and glucose intolerance: a longitudinal study of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetologia 1995;38:839-47.
41. Hanley AJ, Williams K, Stern M, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002; 25:1177-84.
42. Ferrara CM, Goldberg AR Limited value of the homeostasis model assessment to predict insulin resistance in older men with impaired glucose tolerance. Diabetes Care 2001;24:245-9.
43. Dowse GK, Zimmett PZ, Collins VR. Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes 1996;45:1367-72.
44. Tripathy D, Carlsson M, Almgren P et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia study. Diabetes 2000;49:975-80.
45. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC. Impaired glucose tolerance and fasting hyperglycemia have different characteristics. Diabetic Med 2000;17:433-40.
46. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2003;26:868-74.
47. Haffner SM, Stern MR, Hazuda HR Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals - Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
48. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ. Cardiovascular risk factors prior to the development of non-insulin dependent diabetes mellitus in persons with impaired glucose tolerance: The Hoorn Study. J Clin Epidemiol 1997;50:1003-09.
49. Haffner SM, D'Agostino R, Mykkanen L et al. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the insulin resistance and atherosclerosis study. Diabetes Care 1999; 22:562-8.
50. Liese AD, Mayer-Davis EJ, Chambless LE et al. Elevated fasting insulin predicts incident hypertension: the ARIC study. J Hypertension 1999; 17:1169-77.
51. Goff DC, Zaccaro DJ, haffner SM, Saad MF. Insulin sensitivity and the risk of incident hypertension. Diabetes Care 2003;26:805-09.
52. Tai E, Emmanuel SC, Chew S, Tan B, Tan C. Isolated low HDL cholesterol: An insulin-resistant state only in the presence of fasting hypertriglyceridemia. Diabetes 1999;48:1088-92.
53. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arteriosder Thromb Vasc Biol 2004;24:13-18.
54. LeRoith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001;24:588-97.
55. Sattar N, Gaw A, Cherbakova O, Ford I et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19.
56. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events. Circulation 2003;107:391-7.
57. Gaede P, Vedel P, Larsen N, Jensen CV, Parving H, Pedersen O. Multinational intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
58. Tuomilehto J, Lindtrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
59. Pan X, Li G, Hu Y et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care 1997;20:537-44.
60. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
61. Chiasson J, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
62. Buchanan TA, Xiang AH, Peters RK et al. Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women. Diabetes 2002;51:2796-803.
63. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP). Lancet 1999;353:611-16.
64. Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes JAMA 2001;286:1882-5.
65. The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting-enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981-97.
66. Dahlof B, Devereux RB, Kjeldsen et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
67. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
68. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
69. McMurray JJV, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
70. Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes and insulin resistance. Am J Cardiol 2004;93:27C-31C.
71. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Circulation 2003;108:2292-7.